← Oncology Approval Tracker

FDA DECISION ·

Keytruda + chemotherapy

pembrolizumab + fluoropyrimidine- and platinum-containing chemotherapy · Merck

FDA approvalNew or expanded indicationGastroesophageal cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

First-line treatment for adults with HER2-negative gastric or gastroesophageal junction adenocarcinoma that is unresectable locally advanced or metastatic.

LAMPGEN ANALYSIS

Why it matters

The indication added pembrolizumab to a platinum and fluoropyrimidine backbone in the HER2-negative setting.

What research teams should watch

Verify HER2 testing and prior systemic treatment before choosing the gastric combination pathway.

PRIMARY RECORDS

Sources